Scientia Ventures

knowledge is power

In short

Intelligent Investment in Healthcare

In Numbers

31 Companies Funded

5 IPOs



Latest Press

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder


Royalty Pharma

Transforming the funding of life sciences through collaborative capital, Royalty Pharma developed and is the leader in the pharmaceutical royalty business.


ADC Therapeutics

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers.


Intra-Cellular Therapies

Intra-Cellular Therapies is a leading biopharmaceutical company founded by Nobel Prize winner: Paul Greengard...